Reviva Pharmaceuticals Holdings, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OQB
Reviva Pharmaceuticals' 10-K filing highlights positive Phase 3 trial results for brilaroxazine in schizophrenia and outlines the company's strategy for potential FDA approval.
OQB
Reviva Pharmaceuticals' annual report outlines its share structure, warrant details, and a restatement of prior financial statements due to errors in recognizing research and development expenses.